Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0D1EV
|
|||
| Former ID |
DIB008218
|
|||
| Drug Name |
NSC-364432
|
|||
| Synonyms |
SarCNU; Sarcosinamide nitrosourea
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C76-C80; ICD-9: 140-229] | Phase 2 | [1] | |
| Company |
National Cancer Institute
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C6H11ClN4O3
|
|||
| Canonical SMILES |
CN(CC(=O)N)C(=O)N(CCCl)N=O
|
|||
| InChI |
1S/C6H11ClN4O3/c1-10(4-5(8)12)6(13)11(9-14)3-2-7/h2-4H2,1H3,(H2,8,12)
|
|||
| InChIKey |
HYHJFNXFVPGMBI-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 81965-43-7
|
|||
| PubChem Compound ID | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00036660) SarCNU in Treating Patients With Recurrent Malignant Glioma. U.S. National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.